With Positive Data in Hand, Neurocrine and Acadia Prepare for NDAs
Neurocrine Bioscience and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
U.S. boosters surge to all-time high on Omicron fears
/in BNT162b2 (Pfizer and BioNTech), COVID-19 booster shots, COVID-19 Vaccines, Janssen COVID-19 Vaccine (J&J), mRNA-1273/Moderna COVID-19 Vaccine (Moderna)Americans are lining up for booster doses of Covid-19 vaccines at a record pace, with concerns about the newly detected Omicron coronavirus variant spurring millions to get shots, the U.S. government said on December 7.
Studies suggest Pfizer shot may protect only partially against Omicron
/in BNT162b2 (Pfizer and BioNTech), COVID-19 Studies, Omicron (B.1.1.529) (South Africa), R&D, South AsiaThe Omicron variant can partially evade protection from two doses of Pfizer and partner BioNTech’s Covid-19 vaccine, the research head of a laboratory at the Africa Health Research Institute in South Africa said on December 7.
Omicron reported in 57 countries, hospitalizations set to rise, WHO says
/in Hospitalized COVID-19 Patients, Omicron (B.1.1.529) (South Africa), World Health OrganizationThe Omicron variant has been reported in 57 nations and the number of patients needing hospitalization is likely to rise as it spreads, the World Health Organization said on December 8.
Elizabeth Holmes denies misleading investors in trial testimony
/in Business, Elizabeth Holmes, Investors, Legal, Theranos, TrialsTheranos founder Elizabeth Holmes denied making misleading statements about the blood-testing startup during cross-examination on December 7, as her testimony in defense against fraud charges neared its end.
Ionis and AstraZeneca Team Up on Antisense Drug for ATTR
/in Antisense Drugs, AstraZeneca, Business, Deals, Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, R&DCarlsbad, Calif.-based Ionis Pharmaceuticals inked a collaboration deal with AstraZeneca to develop and commercialize eplontersen for transthyretin amyloidosis (ATTR).
New Mexico to join nationwide opioid settlement with drug distributors
/in Business, Drug Distributors, Legal, New Mexico, Settlements, United StatesNew Mexico agreed to join a proposed nationwide settlement worth up to $21 billion resolving claims that the three largest U.S. drug distributors fueled a deadly opioid epidemic, the state’s attorney general said on December 7.
WHO Issues Guidance Against Convalescent Plasma for COVID-19
/in COVID-19 Plasma, Guidance, Plasma, World Health OrganizationThe World Health Organization updated its guidelines for COVID-19 treatments against the use of convalescent plasma for all cases of infection.
U.S. FTC settles with Vyera over Daraprim, Shkreli trial still on
/in Business, Daraprim, Drug Prices, Legal, Martin Shkreli, SettlementsThe U.S. Federal Trade Commission and seven states on December 7 settled claims accusing Vyera Pharmaceuticals of trying to block generic versions of the company’s life-saving drug Daraprim, but are preparing for a Dec. 14 trial against accused mastermind Martin Shkreli.
Recursion and Roche Ink Multibillion Dollar AI Deal
/in Artificial Intelligence, Business, Deals, R&D, RocheThe shares of Utah-based Recursion climbed on December 7 after the company announced entering into a “transformational collaboration” with Swiss pharma giant Roche valued in the billions of dollars to identify and develop up to 40 new medications for neuroscience and oncology.